Cyprus R&D Super-Deduction 2026: How the 120% Tax Break Works — and Stacks with the IP Box

Cyprus has quietly built one of the more generous R&D incentives in the EU. On top of the ordinary deduction for research costs, a business deducts an extra 20% — a "super-deduction" — so every €100 of qualifying spend cuts taxable income by €120. Paired with the 15% corporate income tax rate in force from 1 January 2026 and the IP Box regime, it turns genuine innovation activity into one of the cleanest tax outcomes available to a European company.Income Tax Law N.118(I)/2002, Article 9(1)(d)

This guide explains what the 120% deduction is, exactly what qualifies, how capital-nature R&D is spread over time, and — the question founders ask most — how it interacts with the Cyprus IP Box regime to push the effective rate on innovation income towards 3%.

What is the Cyprus R&D super-deduction?

It is an enhanced deduction under Article 9(1)(d) of the Income Tax Law: a business first deducts 100% of its qualifying scientific research and R&D costs as an ordinary expense, then deducts a further 20% uplift on the same costs. The combined 120% deduction applies to qualifying expenditure incurred between 2025 and 2030.

The base deduction — the ordinary 100% for scientific research and R&D recognised under international accounting standards — is a permanent feature of Cyprus law. What makes it a "super" deduction is the additional 20%, a temporary incentive layered on top. That uplift originally ran for 2022–2024 and has been carried forward so that it now covers expenditure incurred in the years 2025 to 2030, aligning it with Cyprus's broader post-reform innovation agenda.Income Tax Law N.118(I)/2002, Article 9(1)(d) (additional 20% deduction, 2025–2030)

How does the 120% deduction actually work?

The 20% uplift is a deduction on money you never spent. At the 15% corporate rate, €100 of qualifying R&D gives you the ordinary €100 deduction plus a €20 bonus deduction — and that €20 is worth €3 of cash tax saved beyond simply expensing the cost.

The numbers are modest per euro but scale linearly and reward exactly the spending a growing technology business does anyway. A company running a €500,000 annual engineering payroll that qualifies gets a €100,000 additional deduction, worth €15,000 of cash tax every year it spends — on top of deducting the salaries themselves. Because the uplift reduces taxable income, it can also increase or create losses that are carried forward against future profits.Income Tax Law N.118(I)/2002 (corporate income tax rate 15% from 1 January 2026)

What R&D expenditure qualifies?

Scientific research and research and development expenditure, as recognised under international accounting standards, incurred by a person carrying on a business that holds the economic ownership of the intangible asset arising (or that may arise) from that spend. It must be wholly and exclusively for the production of income.

The statute deliberately anchors "R&D" to the accounting definition rather than inventing a separate tax test, which keeps claims grounded in what a company's auditors already recognise. In practice the qualifying pool typically includes:

• Salaries and employment costs of researchers, engineers and developers directly engaged in R&D.
• Consumables and materials used in the research activity.
• R&D outsourced to third parties, where the Cyprus company retains economic ownership of the resulting intangible.
• Costs of developing software, algorithms and other patentable or copyright-protected assets in-house.

Two gating conditions decide most disputed claims. First, economic ownership: the Cyprus business must own the upside of the intangible the R&D creates — contract R&D performed for someone else who owns the output does not qualify for the claimant. Second, the "wholly and exclusively" test that governs all deductible expenses under Article 9. Marketing, routine maintenance and post-launch support dressed up as R&D are the first things a reviewer strips out.Income Tax Law N.118(I)/2002, Article 9(1) (general deductibility) and 9(1)(d)

How is capital-nature R&D expenditure treated?

R&D expenditure of a capital nature — the kind that creates a long-lived intangible rather than a current-year cost — is not deducted all at once. It is spread equally over the tax year in which it is incurred and the five following years, i.e. six years at one-sixth per year.

This matters for cash-flow planning. A €600,000 capitalised development project generates a €100,000 base deduction per year across six years, not a single €600,000 hit. The 20% uplift attaches to qualifying capital-nature R&D as well during the 2025–2030 window, so the incentive is not lost simply because the accounting treats the spend as an asset — but the timing of when you recognise the benefit follows the six-year spread. Getting the revenue-versus-capital characterisation right is an auditor's judgement, which is one more reason claims of any size belong with an ICPAC-licensed firm.Income Tax Law N.118(I)/2002, Article 9(1)(d) (capital-nature R&D spread over six years)

How does the super-deduction work with the IP Box?

They are complementary, not combinable. You cannot claim the 20% R&D uplift and the IP Box deduction on the same expenditure — that would be double relief. Instead they run in sequence: R&D spend builds the "nexus" fraction that lets qualifying income into the IP Box, and the uplift is claimed on R&D you are not routing through the IP Box.

The IP Box, under the same Income Tax Law, lets a Cyprus company deduct 80% of the net qualifying profit from qualifying intellectual property, leaving only 20% taxable. Crucially, the share of IP income that can enjoy the 80% deduction is governed by the OECD modified nexus approach: the more of the underlying R&D the company performs itself (or outsources to unrelated parties), the higher the qualifying fraction.OECD/G20 BEPS Action 5 (modified nexus approach for IP regimes)

So the two reliefs point in the same direction even though they do not stack on the same euro. Real R&D activity in Cyprus is the raw material for both: it earns the 120% deduction while the company is building the asset, and it maximises the nexus fraction so that when the asset earns royalties, licence fees or embedded-IP income, the largest possible slice qualifies for the 80% IP Box deduction. The full mechanics of the nexus formula are covered in our Cyprus IP Box guide.

Can R&D structuring really reach a ~3% effective rate?

On qualifying IP income, yes — but the roughly 3% figure comes from the IP Box, not the R&D uplift. The 80% deduction leaves 20% of qualifying profit taxable at 15%, which is a 3% effective rate. The R&D super-deduction is a separate lever that reduces tax on R&D costs before any IP income is earned.

It is worth being precise, because loose marketing conflates the two. The ~3% headline is arithmetic: 20% x 15% = 3% on the qualifying portion of net IP profit. The R&D super-deduction does not lower that 3% rate — it lowers the tax bill during the build phase, and it feeds the nexus fraction that determines how much of the IP income reaches the 3% rate in the first place. A well-run innovation company therefore sees the benefit twice, in two different tax years: cheaper R&D on the way in, and lightly taxed IP income on the way out.

Who can claim the R&D super-deduction, and until when?

Any person carrying on a business in Cyprus — company or individual — that has economic ownership of the intangible can claim. The 100% base deduction is permanent; the additional 20% uplift applies to qualifying expenditure incurred in the years 2025 to 2030.

There is no minimum spend and no size cap in the statute, but the relief is realistically the preserve of structured, IFRS-reporting companies: the R&D has to be recognised under international accounting standards and defended with contemporaneous records. Note also that claiming an enhanced deduction like this — as with the IP Box or the notional interest deduction — puts a company squarely into full statutory audit territory rather than the lighter review engagement, as explained in our Cyprus audit requirements guide. Companies planning multi-year R&D programmes should map spend against the 2030 sunset now, because the uplift on post-2030 expenditure is not guaranteed to be renewed.Income Tax Law N.118(I)/2002, Article 9(1)(d)

How do you claim it in practice?

The claim is made through the TD4 corporate tax return, built on audited financial statements that identify and support the qualifying R&D. There is no separate application or advance approval — but the burden of proof sits entirely with the company if the Tax Department reviews it.

1. Identify and tag qualifying spendduring the year — payroll of R&D staff, materials, qualifying outsourced work — rather than reconstructing it at year-end.
2. Confirm economic ownership of the resulting intangible sits with the Cyprus company, ideally documented in the development and any outsourcing agreements.
3. Split revenue vs capitalR&D with the auditor, so the six-year spread is applied correctly to capital-nature items.
4. Apply the 20% upliftin the tax computation on qualifying 2025–2030 expenditure that is not being run through the IP Box.
5. File the TD4supported by the audited accounts, and retain the R&D evidence in case of review. Deep tax-technical work like this is best coordinated through licensed advisers — the complete Cyprus tax guide sets out how the pieces fit together.

Zeno is not a law firm. It coordinates independent Cyprus Bar advocates and ICPAC-licensed accountants who advise on and file R&D and IP Box claims. This article is general information, not tax or legal advice.